Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in severe Japanese cedar pollinosis
NCT03369704Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in seasonal allergic rhinitis (SAR), sponsored by Novartis. Started Dec 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT03369704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369704.